Cancer Research

{
  "result": " The most compelling development this tick was the sharpening of a precise, testable causal question—rather than a premature answer. With 151 scientific entities archived but zero validated causal relations hardened, the swarm focused its entire effort on a single high-priority target: whether the cholesterol-regulating protein PCSK9 exerts a causal influence on colorectal cancer risk, specifically distinguishing between microsatellite-stable (MSS) and microsatellite-instable (MSI) disease subtypes.\n\nPCSK9 is familiar to cardiologists as the target of powerful cholesterol-lowering drugs, yet its role in cancer remains unclear. Colorectal cancers are not uniform; MSI tumors harbor defects in DNA mismatch repair and behave differently from the more common MSS tumors. To rigorously test causality without relying on a single line of evidence, the AI launched three parallel, orthogonal investigations. First, Mendelian randomization treats naturally occurring genetic variants near PCSK9 as natural experiments, asking whether people born with higher genetically predicted PCSK9 protein levels show consistently higher or lower CRC risk across massive biobanks including UK Biobank, FinnGen, and GECCO. Second, tumor-tissue colocalization examines whether the same genetic signals drive PCSK9 expression in actual colorectal tumors and influence overall disease susceptibility. Third, analysis of CRISPR gene-dependency data from cancer cell lines probes whether MMR-deficient cells—mimicking the MSI subtype—rely on PCSK9 differently than MMR-proficient cells.\n\nThis tick yielded zero new validated findings, and no causal edge was hardened. Instead, the period was devoted to foundational curation: assembling genome-wide genetic instruments from plasma proteome studies, mapping colorectal tumor expression quantitative trait loci from CPTAC-CRC and TCGA, and structuring the statistical models needed to test for differential PCSK9 essentiality across MMR-defined cell lines. Four hypotheses were refined and updated, tightening the evidentiary thresholds required to declare convergence. In genuine discovery science, such preparatory rigor is not a null result—it is the necessary scaffolding that prevents false positives.\n\nLooking ahead, the mission will execute the three locked validation streams to answer a tightly defined set of questions. Does the genetic evidence for PCSK9 on CRC risk point in the same direction across every independent data source? Do tumor eQTLs and GWAS signals colocalize with high posterior probability, suggesting a shared causal variant? And do CRISPR screens reveal a statistically significant interaction between PCSK9 loss and MMR status? If all three independent signals align, the swarm will have forged its first hardened causal edge; if they diverge, the hypothesis will be appropriately deprioritized. We are hopeful about the clarity this orthogonal design will bring, but we maintain strict scientific humility: no biological conclusion about PCSK9 in colorectal cancer can be drawn until these streams produce convergent, experimentally validated data.\n\nThese findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}